METHODS: In this work, we employed a myc-driven B-cell lymphoma murine model to demonstrate that systemic administration of L19IL2 induced a robust CD8+ T cell-dependent tumor regression across multiple organs without expansion of regulatory T cells. This evidence concerns the gene CD8A and B-cell non-Hodgkin lymphoma.